Track funded deeptech companies, founders and investors across the UK startup ecosystem.
| Date | Startup | Funding | Round | Sector | Location | Connect | Website | Investor1 | Investor2 | Investor3 | Investor4 | Investor5 | Founder(s) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
30 Jun 2026 | Neuronostics BioEP is an EEG-based biomarker platform that analyses routine EEG recordin... | £3,000,000 | |||||||||||
24 Jun 2026 | RQ Bio RQB01 is a long-acting monoclonal antibody candidate developed to provide s... | £87,090,000 US$115,000,000 | |||||||||||
23 Jun 2026 | Astral Systems Astral Systems supplies modular Multi-State Fusion reactors designed as com... | £23,000,000 | |||||||||||
23 Jun 2026 | TRIMTECH Therapeutics TRIMTECH Therapeutics develops proprietary small-molecule degrader platform... | £11,000,000 | |||||||||||
23 Jun 2026 | LabCycle LabCycle's AutoDecon is a system that cleans and processes single-use labor... | £180,000 | |||||||||||
22 Jun 2026 | Houdini Bio Houdini Bio offers a machine learning-guided DNA sequence design platform f... | £1,500,000 | |||||||||||
22 Jun 2026 | CuspAI CuspAI provides a materials discovery platform that uses generative AI to p... | £302,780,000 US$400,000,000 | |||||||||||
4 Jun 2026 | Apoha Apoha makes soft, fluid-based material systems that embed computing functio... | £26,810,000 US$36,000,000 | |||||||||||
2 Jun 2026 | IMU Bioscience IMU Bioscience offers a clinical platform that performs multi-omic analysis... | £39,390,000 US$53,000,000 | |||||||||||
2 Jun 2026 | Hexigone Hexigone provides a responsive additive that integrates into protective coa... | £1,200,000 | Swansea | ||||||||||
1 Jun 2026 | Inherent Faraday is a platform that pairs human researchers with AI agents to suppor... | £37,180,000 US$50,000,000 | |||||||||||
1 Jun 2026 | Laverock Therapeutics Laverock Therapeutics offers a single-cell and AI platform that controls ge... | £2,200,000 | |||||||||||
28 May 2026 | Perceptic Perceptic provides an AI operating system that integrates internal research... | £8,930,000 US$12,000,000 | |||||||||||
27 May 2026 | Mykor MykoSIP is a panel system made from mycelium grown on agricultural and indu... | £4,000,000 | |||||||||||
26 May 2026 | Zonova Z-ROS is a platform that embeds antimicrobial function into medical-device ... | £2,100,000 | |||||||||||
26 May 2026 | SiliXon SiliXon is software for printed circuit board (PCB) design that integrates ... | £1,100,000 | |||||||||||
21 May 2026 | Imperagen Imperagen provides a closed-loop platform that uses AI and robotics to desi... | £5,000,000 | |||||||||||
20 May 2026 | CircuitHub CircuitHub provides an automated electronics manufacturing platform that as... | £21,000,000 | |||||||||||
20 May 2026 | QuberTech QuberTech provides a biotech platform that produces natural rubber from gen... | £3,400,000 | Norwich | ||||||||||
18 May 2026 | Prema Cognition PREMAZ is a digital cognitive testing platform that measures memory precisi... | £550,000 | |||||||||||
12 May 2026 | Tolemy Bio Orbit is an AI-native software platform that connects experimental data and... | £1,210,000 €1,400,000 | |||||||||||
12 May 2026 | Infex Therapeutics RESP-X is a monoclonal antibody that targets Pseudomonas aeruginosa in resp... | £4,300,000 | |||||||||||
12 May 2026 | Isomorphic Labs IsoDDE is an AI-driven engine that generates and evaluates molecules for dr... | £1,500,000,000 £1,500,000,000 | |||||||||||
11 May 2026 | Meatly Meatly develops and operates a pilot facility for producing cultivated meat... | £10,400,000 | |||||||||||
11 May 2026 | Scarlet Therapeutics Scarlet Therapeutics produces lab-grown universal red blood cells from a pr... | £3,200,000 | |||||||||||
6 May 2026 | CellCentric Inobrodib is an oral p300/CBP epigenetic inhibitor. It is intended to treat... | £162,290,000 US$220,000,000 | |||||||||||
6 May 2026 | NunaBio NunaBio provides a cell-free platform for manufacturing synthetic DNA outsi... | £6,500,000 | Newcastle | ||||||||||
6 May 2026 | SugaROx SugaROx's product is a trehalose-6-phosphate biostimulant with a delivery t... | £2,500,000 | |||||||||||
5 May 2026 | Cytospire Therapeutics CYT X300 is a multispecific antibody that acts as a pan-gamma delta T cell ... | £61,000,000 | |||||||||||
28 Apr 2026 | PlaqueTec PlaqueTec offers an intracoronary liquid biopsy device and a linked data pl... | £3,700,000 |

1 Explore 300 UK deeptech startups and their founders, who have collectively raised £7.95B.
2 Easily sort, filter, and compare the UK's top startups — customise the list to your needs.
3 Discover top startups for investment, B2B sales, partnerships, hiring, and industry connections.
You can connect with fast-growing deeptech startups with the full list of recently funded startups from the UK.
Deeptech startups are built on scientific and engineering breakthroughs rather than lightweight software alone. Across the UK, founders are turning advances in AI, robotics, quantum, semiconductors, materials and climate science into commercially scalable companies.
The UK has one of Europe's strongest deeptech ecosystems, supported by world-class universities, specialist research labs and a maturing investor base. London, Cambridge, Oxford, Bristol, Manchester and Edinburgh continue to produce high-growth deeptech companies across pre-seed to growth stages.
Deeptech in this context includes startups where defensible IP, advanced R&D and technical complexity drive long-term value creation. These companies often take longer to scale than traditional software startups, but can create category-defining outcomes with stronger barriers to entry.
Use this page to explore the fastest growing deeptech startups in the UK, then review company profiles for websites, investors, locations and recent funding rounds.
That is our view of the most active deeptech startups in the UK. If you are building in this category, finding investors who understand technical risk, longer R&D cycles and IP-led business models is critical.
Deeptech refers to technology companies built on significant scientific or engineering innovation. Unlike many software-first businesses, deeptech startups usually rely on proprietary research, complex product development and technical teams with domain expertise.
Key deeptech categories in the UK include:
Foundational technologies for model training, inference optimisation, AI hardware and enterprise deployment.
Intelligent machines and autonomous systems for logistics, manufacturing, defence, agriculture and healthcare.
Quantum hardware, software and enabling components for next-generation computing performance.
Breakthrough technologies in energy, carbon management, manufacturing efficiency and resource optimisation.
Novel materials, semiconductors and engineering platforms that unlock better performance across industries.
The UK's research depth and venture ecosystem make it a strong launchpad for deeptech founders building globally competitive companies.
Deeptech startups build companies around scientific, engineering or technical breakthroughs rather than simple software applications. UK deeptech startups often work across AI, robotics, quantum, biotech, semiconductors, advanced materials, space, climate technology and hardware.
The UK is strong in deeptech because of its universities, research institutions, technical talent, spinout activity and specialist investor base. Cambridge, Oxford, London, Bristol, Edinburgh, Manchester and Sheffield are important hubs for science-led and engineering-led startup creation.
Deeptech startups raise funding from angel investors, specialist venture capital firms, university spinout funds, grant programmes and strategic industry partners. They often need more patient capital than software startups because product development, validation and commercialisation can take longer.
Investors in deeptech startups look for defensible intellectual property, strong technical founders, evidence that the technology works and a large commercial market. They also assess whether the company can move from research to repeatable customers without becoming trapped in the lab.
Deeptech startups often take longer to commercialise because they must prove complex technology, build prototypes, protect intellectual property, navigate regulation or integrate with industrial customers. The upside can be significant, but execution risk is usually higher than in standard software startups.